AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Candidiasis: Nystatin is primarily used to treat candidiasis, also known as yeast infection. It is effective against various Candida species, including Candida albicans, which commonly causes infections in the mouth (oral thrush), throat, esophagus, skin, and genital areas.
Oral Thrush: Nystatin is frequently prescribed for the treatment of oral thrush, a fungal infection of the mouth and throat characterized by white patches on the tongue, inner cheeks, and roof of the mouth. It is commonly seen in infants, immunocompromised individuals, and those using corticosteroids or antibiotics.
Esophageal Candidiasis: Nystatin may be used to treat esophageal candidiasis, a fungal infection of the esophagus often seen in individuals with weakened immune systems, such as those with HIV/AIDS or undergoing chemotherapy.
Cutaneous Candidiasis: Nystatin can be applied topically to the skin to treat cutaneous candidiasis, which manifests as red, itchy, and sometimes painful rashes in skin folds, such as the groin, armpits, and under the breasts.
Vaginal Yeast Infections: Although nystatin is not typically the first-line treatment for vaginal yeast infections, it may be used in some cases, especially in pregnant women or those who cannot tolerate azole antifungal medications.
Prevention of Fungal Infections in Neonates: Nystatin oral suspension is sometimes given prophylactically to newborn infants to prevent oral thrush, particularly in premature infants or those with risk factors for fungal infections.
Minimal Systemic Absorption: Nystatin has minimal systemic absorption when administered orally or topically, reducing the risk of systemic side effects. It primarily acts locally at the site of infection.
Safety Profile: Nystatin is generally well-tolerated, and adverse effects are rare. However, some individuals may experience mild side effects such as nausea, vomiting, diarrhea, or irritation at the site of application when used topically.
Drug Interactions: Nystatin has minimal interactions with other medications due to its limited systemic absorption. However, it is always essential to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential interactions.
Resistance: While resistance to nystatin is uncommon, prolonged or inappropriate use of the medication can contribute to the development of resistant strains of Candida.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.4 | -0.4 | |
| ADHD | 3.3 | 0.6 | 4.5 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 1.9 | -2.17 |
| Allergies | 4.8 | 1.1 | 3.36 |
| Allergy to milk products | 0.9 | 0.5 | 0.8 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 2.1 | 3.6 | -0.71 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.5 | 2.4 |
| Ankylosing spondylitis | 2.7 | 0.3 | 8 |
| Anorexia Nervosa | 1.1 | -1.1 | |
| Antiphospholipid syndrome (APS) | 0.5 | 0.3 | 0.67 |
| Asthma | 1.5 | 0.3 | 4 |
| Atherosclerosis | 0.9 | 1.1 | -0.22 |
| Atrial fibrillation | 2.4 | 1 | 1.4 |
| Autism | 6.5 | 4.7 | 0.38 |
| Barrett esophagus cancer | 0.5 | 0.1 | 4 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 0.8 | 1.2 | -0.5 |
| Brain Trauma | 0.8 | 0.2 | 3 |
| Cancer (General) | 0.4 | 2.8 | -6 |
| Carcinoma | 3.4 | 2.4 | 0.42 |
| Celiac Disease | 1.5 | 3.8 | -1.53 |
| Cerebral Palsy | 1.2 | 0.8 | 0.5 |
| Chronic Fatigue Syndrome | 5.3 | 5.3 | 0 |
| Chronic Kidney Disease | 1.7 | 0.6 | 1.83 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.2 | 3 |
| Chronic Urticaria (Hives) | 1.3 | 0.1 | 12 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 0.7 | -0.4 |
| Colorectal Cancer | 1.7 | 0.8 | 1.13 |
| Constipation | 0.4 | 0.5 | -0.25 |
| Coronary artery disease | 0.6 | 1.2 | -1 |
| COVID-19 | 9.5 | 8 | 0.19 |
| Crohn's Disease | 4.8 | 2.7 | 0.78 |
| cystic fibrosis | 0.5 | 0.6 | -0.2 |
| deep vein thrombosis | 0.5 | 0.2 | 1.5 |
| Depression | 6.3 | 5.1 | 0.24 |
| Dermatomyositis | 0.1 | 0.4 | -3 |
| Eczema | 0.6 | 0.8 | -0.33 |
| Endometriosis | 2.2 | 1 | 1.2 |
| Eosinophilic Esophagitis | 0.5 | -0.5 | |
| Epilepsy | 1.7 | 1.2 | 0.42 |
| Fibromyalgia | 1.3 | 1.4 | -0.08 |
| Functional constipation / chronic idiopathic constipation | 3.2 | 2.4 | 0.33 |
| gallstone disease (gsd) | 1.9 | 0.4 | 3.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 1 | -1 |
| Generalized anxiety disorder | 0.9 | 2 | -1.22 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.2 | -0.2 | |
| Graves' disease | 1 | 1.3 | -0.3 |
| Halitosis | 0.7 | 0.1 | 6 |
| Hashimoto's thyroiditis | 2.5 | 0.9 | 1.78 |
| Hidradenitis Suppurativa | 0.3 | 0.5 | -0.67 |
| High Histamine/low DAO | 1.1 | 0.5 | 1.2 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.1 | 6 |
| hyperglycemia | 0.2 | 1.2 | -5 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.4 | 1 |
| hypersomnia | 0.8 | -0.8 | |
| hypertension (High Blood Pressure | 1.4 | 3.6 | -1.57 |
| Hypothyroidism | 1.5 | -1.5 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 1.7 | -1.7 | |
| Inflammatory Bowel Disease | 2.2 | 3.9 | -0.77 |
| Insomnia | 0.7 | 0.2 | 2.5 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.8 | 0.4 | 1 |
| Irritable Bowel Syndrome | 2.6 | 2.1 | 0.24 |
| Liver Cirrhosis | 3.5 | 2.5 | 0.4 |
| Long COVID | 4.6 | 6.6 | -0.43 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.6 | 1.1 | -0.83 |
| Mast Cell Issues / mastitis | 0.2 | 0.7 | -2.5 |
| ME/CFS with IBS | 0.8 | 2.8 | -2.5 |
| ME/CFS without IBS | 1.7 | 1.8 | -0.06 |
| Menopause | 2.2 | 2.2 | |
| Metabolic Syndrome | 5.5 | 4.9 | 0.12 |
| Mood Disorders | 8.9 | 5.6 | 0.59 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.5 | 0.4 |
| Multiple Sclerosis | 4.4 | 1.2 | 2.67 |
| Multiple system atrophy (MSA) | 0.2 | 1 | -4 |
| neuropathic pain | 0.6 | -0.6 | |
| Neuropathy (all types) | 0.6 | 0.2 | 2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 4.3 | -1.39 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.6 | 2 |
| Obesity | 7 | 2.9 | 1.41 |
| obsessive-compulsive disorder | 3.8 | 3.1 | 0.23 |
| Osteoarthritis | 0.8 | 0.1 | 7 |
| Osteoporosis | 1.7 | 0.8 | 1.13 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 4.9 | 2.3 | 1.13 |
| Polycystic ovary syndrome | 1.2 | 1.4 | -0.17 |
| Postural orthostatic tachycardia syndrome | 0.3 | 0.6 | -1 |
| Premenstrual dysphoric disorder | 1.3 | 1.3 | |
| primary biliary cholangitis | 0.4 | 0.6 | -0.5 |
| Psoriasis | 3.8 | 0.5 | 6.6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 2.8 | 0.43 |
| Rosacea | 1.4 | 0.3 | 3.67 |
| Schizophrenia | 5.9 | 1.5 | 2.93 |
| scoliosis | 0.2 | 0.4 | -1 |
| Sjögren syndrome | 2.5 | 2.2 | 0.14 |
| Sleep Apnea | 1.2 | 1.3 | -0.08 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.4 | 1.75 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 1 | -1.5 |
| Stress / posttraumatic stress disorder | 1.6 | 2.1 | -0.31 |
| Systemic Lupus Erythematosus | 2.7 | 1.4 | 0.93 |
| Tic Disorder | 0.5 | 1.2 | -1.4 |
| Tourette syndrome | 0 | 0.2 | 0 |
| Type 1 Diabetes | 2.7 | 0.8 | 2.38 |
| Type 2 Diabetes | 5.2 | 3.2 | 0.63 |
| Ulcerative colitis | 2.3 | 2.8 | -0.22 |
| Unhealthy Ageing | 3.5 | 1 | 2.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.81.24 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.81.24 ]
